Physician profile
Allan A Hunter
NPI 1184748030
$2,908.74
in general payments reported to CMS, 2019-2025
22 companies · $863 in 2025
The $863 reported for 2025 was more than what a typical Retina Specialist provider received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $392 · 2020: $149 · 2021: $305 · 2022: $313 · 2023: $399 · 2024: $488 · 2025: $863.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,749.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,749.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $512.40 | 2019-2025 | |
| Genentech USA, INC. | $452.35 | 2019-2025 | Vabysmo, Susvimo |
| Novartis Pharmaceuticals Corporation | $371.16 | 2019-2021 | |
| Apellis Pharmaceuticals, INC. | $275.71 | 2022-2025 | Syfovre |
| Regeneron Healthcare Solutions, INC. | $266.69 | 2020-2025 | Eylea, Eylea Hd |
| Allergan, INC. | $166.90 | 2019-2021 | |
| Alcon Vision LLC | $147.48 | 2021-2022 | |
| Astellas Pharma US INC | $135.22 | 2023-2025 | Izervay |
| Ani Pharmaceuticals, INC. | $105.27 | 2024-2025 | Yutiq, Iluvien, Purified Cortrophin Gel |
| Rxsight INC | $100.48 | 2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
| Alimera Sciences, INC. | $98.68 | 2022-2024 | Iluvien, Yutiq |
| Genentech, INC. | $66.70 | 2019 | |
| Mallinckrodt Hospital Products INC. | $55.35 | 2025 | Acthar |
| Eyepoint US, INC. | $53.62 | 2020-2023 | |
| Sight Sciences, INC. | $40.81 | 2025 | Sion Surgical Instrument, Omni Surgical System |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $23.73 | 2022 | |
| Coherus Oncology, INC. | $21.54 | 2022 | |
| Kala Pharmaceuticals, INC. | $14.65 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allan Hunter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.